(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 November 2005 (24.11.2005)

PCT

(10) International Publication Number
WO 2005/111047 A1

(51) International Patent Classification[7]: C07D 519/00, 471/04, A61K 31/437

(21) International Application Number: PCT/EP2005/052264

(22) International Filing Date: 17 May 2005 (17.05.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
04102171.8 17 May 2004 (17.05.2004) EP

(71) Applicant *(for all designated States except US)*: **TIBOTEC PHARMACEUTICALS LTD.** [IE/IE]; Little Island, Co Cork (IE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **KESTELEYN, Bart Rudolf Romanie** [BE/BE]; Weidelandstraat 18, B-9290 Berlare (BE). **RABOISSON, Pierre Jean-Marie Bernard** [FR/BE]; Sint Pancratiuslaan 26, B-1933 Sterrebeek (BE). **SURLERAUX, Dominique Louis Nestor Ghislain** [BE/BE]; Rue de la Scaillée, 13, B-1440 Braine-le-château (BE). **HACHE, Geerwin Yvonne Paul** [BE/BE]; Rochuslei 58, B-2930 Brasschaat (BE). **VENDEVILLE, Sandrine, Marie, Helene** [FR/BE]; Avenue du General Bernheim no. 33, B-1040 Etterbeek (BE). **PEETERS, Annick Ann** [BE/BE]; Den Brem 70, B-2610 Wilrijk (BE). **WIGERINCK, Piet, Tom, Bert, Paul** [BE/BE]; Kardinaal Cardijnstraat 29, B-2840 Terhagen (BE).

(74) Agent: **WANTE, Dirk**; Tibotec-Virco Comm. VA, Generaal De Wittelaan L 11B 3, B-2800 Mechelen (BE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations*


— *of inventorship (Rule 4.17(iv)) for US only*

**Published:**

— *with international search report*

*[Continued on next page]*

(54) Title: 1-HETEROCYCLYL-1,5-DIHYDRO-PYRIDO[3,2-B]INDOL-2-ONES




(57) Abstract: 1-heterocyclyl-1,5-dihydro-pyrido[3,2-b]indo 1-2-ones of formula (I): the *N*-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites thereo f, wherein n is 1, 2 or 3; $R^1$ is hydrogen, cyano, halo, substituted carbonyl, methanimidamidyl, *N*-hydroxy- methanimidamidyl, mono- or di($C_{1-4}$alkyl)methanimidamidyl, $Het_1$ or $Het_2$; X is $NR_2$, O, S, SO, $SO_2$; $R^2$ is hydrogen, $C_{1-10}$alkyl, $C_{2-10}$alkenyl, $C_{3-7}$cycloalkyl, which are optionally substituted; $R^2$ is aryl subst ituted with $-COOR^4$ ; or $R^2$ is: (b-1); (b-2); $-C_pH_{2p}-CH(OR^{14})-C_qH_{2q}-R^{15}$ (b-3); $-CH_2-CH_2-(O-CH_2-CH_2)_m-OR^{14}$ (b-4); $-CH_2-CH_2-(O-CH_2-CH_2)_m-NR^{5a}R^{5b}$ (b-5); $-a^1=a^2-a^3=a^4-$ is -CH=CH-CH=CH-; -N=CH-CH=CH-; -CH=N-CH=CH-; -CH=CH-N=CH-; -CH=CH-CH=N-; wherein hydrogen atoms in (c-1) -(c-5) may be replaced by certain radicals; $R^3$ is a monocyclic or bicyclic aromatic heterocyclic ring system that can be substituted.

WO 2005/111047 A1

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*